Occupational asthma from tafenoquine in the pharmaceutical industry: implications for QSAR

被引：7

作者：

Cannon, J. ^{[1
,2
]}

Fitzgerald, B. ^{[1
,2
]}

Seed, M. ^{[3
]}

Agius, R. ^{[3
]}

Jiwany, A. ^{[4
]}

Cullinan, P. ^{[1
,2
]}

机构：

[1] Royal Brompton & Harefield NHS Trust, Dept Occupat & Environm Med, London SW3 6LR, England

[2] Univ London Imperial Coll Sci Technol & Med, London, England

[3] Univ Manchester, Ctr Occupat & Environm Hlth, Manchester, Lancs, England

[4] GlaxoSmithKline, Dept Occupat Hlth, Brentford, Middx, England

来源：

OCCUPATIONAL MEDICINE-OXFORD | 2015年 / 65卷 / 03期

关键词：

Asthma hazard index; respiratory sensitizer; tafenoquine; HAZARD; RELAPSE;

D O I：

10.1093/occmed/kqu193

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

We report occupational asthma and rhinitis in a formulation pharmacist, employed in the development of tafenoquine. Tafenoquine is a new anti-malarial drug in development; the pure drug substance has an asthma hazard index of zero and previously was not known to be a respiratory sensitizing agent. The implications of this finding for the refinement of quantitative structural analysis of asthmagenic chemicals are discussed.

引用

页码：256 / 258

页数：3

共 7 条

[1] STRUCTURE ACTIVITY HYPOTHESES IN OCCUPATIONAL ASTHMA CAUSED BY LOW-MOLECULAR-WEIGHT SUBSTANCES [J].

AGIUS, RM ;

NEE, J ;

MCGOVERN, B ;

ROBERTSON, A .

ANNALS OF OCCUPATIONAL HYGIENE, 1991, 35 (02) :129-137

[2]

Centre for Occupational and Environmental Health University of Manchester, OCC ASTHM HAZ RES

[3] Development of Mechanism-Based Structural Alerts for Respiratory Sensitization Hazard Identification [J].

Enoch, S. J. ;

Seed, M. J. ;

Roberts, D. W. ;

Cronin, M. T. D. ;

Stocks, S. J. ;

Agius, R. M. .

CHEMICAL RESEARCH IN TOXICOLOGY, 2012, 25 (11) :2490-2498

[4] Relationship between chemical structure and the occupational asthma hazard of low molecular weight organic compounds [J].

Jarvis, J ;

Seed, MJ ;

Elton, RA ;

Sawyer, L ;

Agius, RM .

OCCUPATIONAL AND ENVIRONMENTAL MEDICINE, 2005, 62 (04) :243-250

[5] Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study [J].

Llanos-Cuentas, Alejandro ;

Lacerda, Marcus V. ;

Rueangweerayut, Ronnatrai ;

Krudsood, Srivicha ;

Gupta, Sandeep K. ;

Kochar, Sanjay K. ;

Arthur, Preetam ;

Chuenchom, Nuttagarn ;

Moehrle, Joerg J. ;

Duparc, Stephan ;

Ugwuegbulam, Cletus ;

Kleim, Joerg-Peter ;

Carter, Nick ;

Green, Justin A. ;

Kellam, Lynda .

LANCET, 2014, 383 (9922) :1049-1058

[6] Further validation of computer-based prediction of chemical asthma hazard [J].

Seed, Martin ;

Agius, Raymond .

OCCUPATIONAL MEDICINE-OXFORD, 2010, 60 (02) :115-120

[7] Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse [J].

Walsh, DS ;

Wilairatana, P ;

Tang, DB ;

Heppner, DG ;

Brewer, TG ;

Krudsood, S ;

Silachamroon, U ;

Phumratanaprapin, W ;

Siriyanonda, D ;

Looareesuwan, S .

CLINICAL INFECTIOUS DISEASES, 2004, 39 (08) :1095-1103

← 1 →